Despite being a newly created company, Dynakin because of its human capital and its founding principles has a high technological potential both at present and future. R&D is recognized by Dynakin’s private and public investors as one of the organization’s keys to success. Over 80% of its personnel are PhD’s and last year over 30% of Dynakin’s budget was dedicated to R&D in the pharmaceutical services.

Technological potential is determined both by the expertise of our staff and by the relationships built in Spain and abroad with other actors involved in the R&D system such as universities, research centers, biotechnological companies and pharmaceutical industry.

Currently, the main research lines developed by Dynakin are:

·        Personalized Medicine

·        Prediction of First-in-Human Dose

·        Drug-Disease models

·        Optimization and adaptation of trials in pediatric populations

·        Biomarkers of efficacy and pharmacogenetics in oncology